Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19/anti-CD3/anti-CD2 trispecific antibody PIT565

A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell co-stimulatory receptor CD2, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/anti-CD3/anti-CD2 trispecific antibody PIT565 targets and binds to CD3 and CD2 on T cells and CD19 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
Synonym:anti-CD19/CD3/CD2 trispecific antibody PIT565
CD19 x CD3 x CD2 trispecific antibody PIT565
Code name:PIT 565
PIT-565
PIT565
Search NCI's Drug Dictionary